These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 21957195)

  • 1. Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.
    Frisch BJ; Ashton JM; Xing L; Becker MW; Jordan CT; Calvi LM
    Blood; 2012 Jan; 119(2):540-50. PubMed ID: 21957195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
    Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS
    Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid at subtoxic dose extends osteoblastic stage span of primary human osteoblasts.
    Zara S; De Colli M; di Giacomo V; Zizzari VL; Di Nisio C; Di Tore U; Salini V; Gallorini M; Tetè S; Cataldi A
    Clin Oral Investig; 2015 Apr; 19(3):601-11. PubMed ID: 25055744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosmarinic acid exerts an antiosteoporotic effect in the RANKL-induced mouse model of bone loss by promotion of osteoblastic differentiation and inhibition of osteoclastic differentiation.
    Lee JW; Asai M; Jeon SK; Iimura T; Yonezawa T; Cha BY; Woo JT; Yamaguchi A
    Mol Nutr Food Res; 2015 Mar; 59(3):386-400. PubMed ID: 25380345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
    Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bad to the bone.
    Lane SW
    Blood; 2012 Jan; 119(2):323-5. PubMed ID: 22247518
    [No Abstract]   [Full Text] [Related]  

  • 8. Osteoblasts protect AML cells from SDF-1-induced apoptosis.
    Kremer KN; Dudakovic A; McGee-Lawrence ME; Philips RL; Hess AD; Smith BD; van Wijnen AJ; Karp JE; Kaufmann SH; Westendorf JJ; Hedin KE
    J Cell Biochem; 2014 Jun; 115(6):1128-37. PubMed ID: 24851270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.
    Cheung LC; Tickner J; Hughes AM; Skut P; Howlett M; Foley B; Oommen J; Wells JE; He B; Singh S; Chua GA; Ford J; Mullighan CG; Kotecha RS; Kees UR
    Leukemia; 2018 Nov; 32(11):2326-2338. PubMed ID: 29740160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dioxins interfere with differentiation of osteoblasts and osteoclasts.
    Korkalainen M; Kallio E; Olkku A; Nelo K; Ilvesaro J; Tuukkanen J; Mahonen A; Viluksela M
    Bone; 2009 Jun; 44(6):1134-42. PubMed ID: 19264158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo.
    Lymperi S; Ersek A; Ferraro F; Dazzi F; Horwood NJ
    Blood; 2011 Feb; 117(5):1540-9. PubMed ID: 21131587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
    Haider MT; Holen I; Dear TN; Hunter K; Brown HK
    Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stromal cells from patients with acute myeloid leukemia have altered capacity to expand differentiated hematopoietic progenitors.
    Chandran P; Le Y; Li Y; Sabloff M; Mehic J; Rosu-Myles M; Allan DS
    Leuk Res; 2015 Apr; 39(4):486-93. PubMed ID: 25703353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia.
    Stopka T; Zakova D; Fuchs O; Kubrova O; Blafkova J; Jelinek J; Necas E; Zivny J
    Leukemia; 2000 Jul; 14(7):1247-52. PubMed ID: 10914549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fibroblast growth factor 2 on stromal cell-derived factor 1 production by bone marrow stromal cells and hematopoiesis.
    Nakayama T; Mutsuga N; Tosato G
    J Natl Cancer Inst; 2007 Feb; 99(3):223-35. PubMed ID: 17284717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts.
    Hoshino A; Iimura T; Ueha S; Hanada S; Maruoka Y; Mayahara M; Suzuki K; Imai T; Ito M; Manome Y; Yasuhara M; Kirino T; Yamaguchi A; Matsushima K; Yamamoto K
    J Biol Chem; 2010 Sep; 285(37):28826-37. PubMed ID: 20571024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone loss induced by Runx2 over-expression in mice is blunted by osteoblastic over-expression of TIMP-1.
    Schiltz C; Prouillet C; Marty C; Merciris D; Collet C; de Vernejoul MC; Geoffroy V
    J Cell Physiol; 2010 Jan; 222(1):219-29. PubMed ID: 19780057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoclast activity modulates B-cell development in the bone marrow.
    Mansour A; Anginot A; Mancini SJ; Schiff C; Carle GF; Wakkach A; Blin-Wakkach C
    Cell Res; 2011 Jul; 21(7):1102-15. PubMed ID: 21321604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.